BBIO Q2 2022 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$74M+36.5% YoY

Gross Profit

$73M99.1% margin

Operating Income

-$80M-108.7% margin

Net Income

-$10M-13.4% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+4253.4%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$34M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$862M

Total Liabilities

$1.9B

Stockholders' Equity

-$1.0B

Cash & Equivalents

$470M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$74M	$54M	+36.5%
Gross Profit	$73M	$54M	+35.5%
Operating Income	-$80M	-$94M	+14.7%
Net Income	-$10M	-$96M	+89.8%

Revenue Segments

License and Service

$74M100%